Page 761 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPtEr 53 Juvenile Idiopathic Arthritis 733

9. Li YR, Zhao SD, Li J, et al. Genetic sharing and heritability of paediatric arthritis: initiation and safety monitoring of therapeutic agents for the
age of onset autoimmune diseases. Nat Commun 2015;6:8442. treatment of arthritis and systemic features. Arthritis Care Res (Hoboken)
10. Meyer B, Chavez RA, Munro JE, et al. DNA methylation at IL32 in 2011;63(4):465–82.
juvenile idiopathic arthritis. Sci Rep 2015;5:11063. 25. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011
11. Zonneveld-Huijssoon E, Albani S, Prakken BJ, et al. Heat shock protein American College of Rheumatology recommendations for the treatment
bystander antigens for peptide immunotherapy in autoimmune disease. of juvenile idiopathic arthritis: recommendations for the medical therapy
Clin Exp Immunol 2013;171(1):20–9. of children with systemic juvenile idiopathic arthritis and tuberculosis
12. Stoll ML. Gut microbes, immunity, and spondyloarthritis. Clin Immunol screening among children receiving biologic medications. Arthritis
2015;159(2):134–42. Rheum 2013;65(10):2499–512.
13. Arvikar SL, Steere AC. Diagnosis and treatment of Lyme arthritis. Infect 26. Wallace CA, Giannini EH, Huang B, et al. American College of
Dis Clin North Am 2015;29(2):269–80. Rheumatology provisional criteria for defining clinical inactive disease in
14. Sen ES, Dick AD, Ramanan AV. Uveitis associated with juvenile idiopathic select categories of juvenile idiopathic arthritis. Arthritis Care Res
arthritis. Nat Rev Rheumatol 2015;11(6):338–48. (Hoboken) 2011;63(7):929–36.
15. Wang Y, Pei F, Wang X, et al. Meta-analysis: diagnostic accuracy of 27. Braun J, Kiltz U, Heldmann F, et al. Emerging drugs for the treatment of
anti-cyclic citrullinated peptide antibody for juvenile idiopathic arthritis. axial and peripheral spondyloarthritis. Expert Opin Emerg Drugs
J Immunol Res 2015;2015:915276. 2015;20(1):1–14.
16. Miyara M, Ito Y, Sakaguchi S. TREG-cell therapies for autoimmune 28. Schiappapietra B, Varnier G, Rosina S, et al. Glucocorticoids in juvenile
rheumatic diseases. Nat Rev Rheumatol 2014;10(9):543–51. idiopathic arthritis. Neuroimmunomodulation 2015;22(1-2):112–18.
17. Cimaz R, Moretti D, Pagnini I, et al. What do cytokine profiles tell us 29. Jinesh S. Pharmaceutical aspects of anti-inflammatory TNF-blocking
about subsets of juvenile idiopathic arthritis? Curr Rheumatol Rep drugs. Inflammopharmacology 2015;23(2-3):71–7.
2012;14(2):150–4. 30. Hurd A, Beukelman T. Infectious complications in juvenile idiopathic
18. Zhang M, Behrens EM, Atkinson TP, et al. Genetic defects in cytolysis arthritis. Curr Rheumatol Rep 2013;15(5):327.
in macrophage activation syndrome. Curr Rheumatol Rep 2014;16(9): 31. Mannion ML, Beukelman T. Risk of malignancy associated with biologic
439. agents in pediatric rheumatic disease. Curr Opin Rheumatol
19. Stoll ML, Punaro M. Psoriatic juvenile idiopathic arthritis: a tale of two 2014;26(5):538–42.
subgroups. Curr Opin Rheumatol 2011;23(5):437–43. 32. Verazza S, Negro G, Marafon D, et al. Possible discontinuation of
20. Malleson PN, Mackinnon MJ, Sailer-Hoeck M, et al. Review for the therapies after clinical remission in juvenile idiopathic arthritis. Clin Exp
generalist: The antinuclear antibody test in children - When to use it and Rheumatol 2013;31(4 Suppl. 78):S98–101, quiz S102-7.
what to do with a positive titer. Pediatr Rheumatol Online J 2010;8:27. 33. Ravelli A, Minoia F, Davì S, et al. 2016 Classification Criteria for
21. Ording Muller LS, Humphries P, Rosendahl K. The joints in juvenile Macrophage Activation Syndrome Complicating Systemic Juvenile
idiopathic arthritis. Insights Imaging 2015;6(3):275–84. Idiopathic Arthritis: A European League Against Rheumatism/American
22. Vaid YN, Dunnavant FD, Royal SA, et al. Imaging of the College of Rheumatology/Paediatric Rheumatology International Trials
temporomandibular joint in juvenile idiopathic arthritis. Arthritis Care Organisation Collaborative Initiative. Arthritis Rheumatol
Res (Hoboken) 2014;66(1):47–54. 2016;42(7):566–76.
23. Cattalini M, Khubchandani R, Cimaz RJ. When flexibility is not 34. Weaver LK, Behrens EM. Hyperinflammation, rather than
necessarily a virtue: a review of hypermobility syndromes and chronic or hemophagocytosis, is the common link between macrophage activation
recurrent musculoskeletal pain in children. Pediatr Rheumatol Online J syndrome and hemophagocytic lymphohistiocytosis. Curr Opin
2015;13:40. Rheumatol 2014;26(5):562–9.
24. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of
Rheumatology recommendations for the treatment of juvenile idiopathic